Board of Directors and management of Prostatype Genomics AB enter into agreements regarding lock up
Prostatype Genomics AB (“Prostatype” or “the Company”) hereby announces that members of the Board and management of the Company have entered into agreements regarding prolonged lock up of their holdings in the Company. The lock up refers to 100 percent of each of the parties’ holdings, for a period lasting until the 30th of April 2022.
In connection with the IPO of Prostatype, members of the Board, as well as management and other shareholders entered into agreement regarding lock up. These agreements expire on the 3rd of November 2021, which is 12 months after the first day of trading in Prostatype’s shares and warrants on Nasdaq First North Growth Market.
The Board of Directors as well as management have now, based on that the original agreements will expire shortly, entered into prolonged agreements regarding lock up. The parties who have entered into the agreements are Creathor Venture Fund III (SCS) SICAR, Creathor Venture Fund III Parallel (SCS) SICAR, Board members Håkan Englund, Michael Häggman, Anders Lundberg, CEO Fredrik Persson and CFO Michael af Winklerfelt. Together, these shareholders own approximately 30 percent of the total shares in the Company.
This disclosure contains information that Prostatype Genomics AB is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person, on 27-10-2021 10:00 CET.
Svensk Kapitalmarknadsgranskning AB, 011-32 30 732, [email protected]
Isofol Medical AB (publ) will not reach 300 PFS events in the AGENT study with current censoring rules based on FDA decision
GOTHENBURG, Sweden, December 3, 2021 – Isofol Medical AB (publ) (Nasdaq Stockholm: ISOFOL), announced today that the U.S. Food and Drug Administration (FDA) denied a request from the company to adjust the analysis of the pivotal AGENT study’s secondary endpoint of progression-free survival (PFS). Ho...
Isofol Medical AB (publ) når inte 300 PFS-händelser i AGENT-studien med nuvarande censureringsregler baserat på FDA-beslut
GÖTEBORG, Sverige, 3 december 2021 - Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL) tillkännagav idag att den amerikanska läkemedelsmyndigheten FDA avslagit en förfrågan från bolaget att få justera analysen av den pivotala AGENT-studiens sekundära effektmått 300 händelser av progressionsfri öv...
Rättelse: AroCell valberedning utsedd inför årsstämma 2022
Valberedningen, som är utsedd enligt de principer som antogs på årsstämman den 6 maj 2021 består av:• Clas Runnberg, representerar Labbex Förvaltnings AB• Jon Eiken, representerar eget aktieinnehav• Mikael Lönn, representerar eget aktieinnehavValberedningen ska före årsstämman 2022 utarbeta förslag...
Correction: AroCell nomination committee for the AGM 2022
The nomination committee, which is appointed in accordance with the principles adopted by the annual general meeting on May 6, 2021, consists of: • Clas Runnberg, represents Labbex Förvaltnings AB• Jon Eiken, represents his own shares• Mikael Lönn, represents his own shares The nomination committee...